| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Aryl hydrocarbon receptor nuclear translocator;ARNT protein;Class E basic helix-loop-helix protein 2;bHLHe2;Dioxin receptor, nuclear translocator;Hypoxia-inducible factor 1-beta;HIF-1-beta;HIF1-beta;ARNT;BHLHE2; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human Fragilis |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-IFITM3 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ADAC-9; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-Fragilis IFITM3 Monoclonal Antibody catalog # M02265. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human.
Key elements and design rationale
- Target: IFITM3 (Aryl hydrocarbon receptor nuclear translocator).
- Antibody format: Monoclonal; clone ADAC-9; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
IFITM3 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Required for activity of the Ah (dioxin) receptor. This protein is required for the ligand-binding subunit to translocate from the cytosol to the nucleus after ligand binding. The complex then initiates transcription of genes involved in the activation of PAH procarcinogens. The heterodimer with HIF1A or EPAS1/HIF2A functions as a transcriptional regulator of the adaptive response to hypoxia. Reported cellular localization context: Nucleus. Tissue expression notes (as provided): Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable. .
Research relevance and current trends
- Research context keywords from the source record include: Developmental Biology,Germ Cell Markers,Germline Stem Cells,Reproduction,Stem Cells.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate IFITM3 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect IFITM3 expression by Western blot in cell or tissue lysates, Detect IFITM3 in FFPE tissue sections by immunohistochemistry, Localize IFITM3 by immunofluorescence/immunocytochemistry in cultured cells, Quantify IFITM3-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 16 kDa; calculated MW: 86636 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 16 kDa
- Cellular localization (provided): Nucleus.
- Tissue details (provided): Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
